Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Innorna
Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment
Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...
Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015
Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...
Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...
Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology
Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...